Gene Editing for Rare Skin Disorder Junctional Epidermolysis Bullosa | Wed. Sept. 21, 2022 | 3:00 pm – 4:30 pm CEST / 9:00 am – 10:30 am EST | Free CMN Live Webinar

On-demand webinar is available - Follow this link

 

Gene Editing for Rare Skin Disorder Junctional Epidermolysis Bullosa

Webinar Programme:

  • 15.00 Welcome and introduction by CRISPR Medicine News
  • 15.05 Johannes Bischof, Dr., EB House Austria | Gene Editing for Rare Skin Disorder Junctional Epidermolysis Bullosa
  • 15.50 Q & A with Johannes Bischof
  • 16.25 Close by CRISPR Medicine News

 

Speaker | Title:

Johannes Bischof, Dr., EB House Austria, Department of Dermatology, University Hospital of the Paracelsus Medical University Salzburg, Austria | Gene Editing for Rare Skin Disorder Junctional Epidermolysis Bullosa

CMN interview

CMN Webinar: Gene Editing for Rare Skin Disorder Junctional Epidermolysis Bullosa
Speakers

Johannes Bischof, Dr., EB House Austria

Johannes Bischof, Dr., EB House Austria

Dr. Johannes Bischof, Postdoc at the Koller working group for Epidermolysis Bullosa Research

EB House Austria, Department of Dermatology, University Hospital of the Paracelsus Medical University Salzburg, Austria

Read our CMN interview with Dr. Bischof from July 2022.

Interested in hosting a webinar on CMN?

Contact us to learn more about our Client Webinar package.

+20k readers | +10k followers | Top-1 CRISPR News Site | sales@crisprmedicinenews.com

CMN Webinar: Gene Editing for Rare Skin Disorder Junctional Epidermolysis Bullosa
CMN Webinars - Your Gateway to CRISPR Medicine

If you have any questions or request for webinars, please contact us at: sales@crisprmedicinenews.com

Future CMN Webinars will be listed here.

Always stay updated - Sign up to weekly newsletter.

CMN Articles - Delivery

 

 

Therapeutic Gene Editing. A Lot Done, a Lot More...
CMN Interview

Feb. 5, 2024

For the inaugural episode of CMN Live on 26th January 2024, we spoke with Eric Kmiec, Ph.D. about the successes of therapeutic gene editing to date,...

Gene-Editing Tools: Delivery Methods and...
CMN Special

Jan. 22, 2024

Gene-editing systems, especially CRISPR-Cas9, have revolutionised genome editing, offering potential cures for genetic disorders, cancers, and other...

Calm Before the Storm: Recent Progress in AAV...
Nov. 20, 2023

AAV trailblazer Nicole Paulk, formerly of UCSF, speaks about the latest developments in AAV-based gene therapies and her new company, Siren...

Using Engineered Viruses to Deliver CRISPR...
Oct. 23, 2023

In a recent study, researchers in Denmark engineered lentiviruses to incorporate Cas9 protein fused to viral proteins to allow packaging of Cas9 into...

A GEENIE in a Bottle: CyGenica’s Unique Non-Viral...
Sponsored content

Oct. 12, 2022

Irish-Indian company CyGenica is on a mission to solve the huge challenge surrounding targeted intracellular delivery of gene-editing and other...

Multiplex CRISPR Merges With Click Chemistry
Aug. 8, 2022

At a length of around 100 nucleotides, single guide RNAs are not synthesised efficiently. However, thanks to click chemistry, they can now be...

Functionalised Nanocapsules Enable Effective...
Jun. 27, 2022

Extended survival times and inhibited growth of patient-derived glioblastoma brain tumours have been achieved in mice with CRISPR-Cas9 mediated...

In Vivo Prime Editing in the Mouse Liver Suggests...
May. 2, 2022

A CRISPR-based therapy for the metabolic liver disease phenylketonuria (PKU) has moved one step forward. In vivo prime editing in neonate mice...

close
Search CRISPR Medicine